Target intelligence / Profile preview

Multiple endogenous wound-healing pathways

Molecular classification
Other
01

Overview

Multiple endogenous wound-healing pathways refers to the highly coordinated physiological processes—hemostasis, inflammation, proliferation, and remodeling—that restore tissue integrity after injury (StatPearls, 2023). These pathways involve the integrated action of various cell types, including platelets, neutrophils, macrophages, fibroblasts, and endothelial cells, which are regulated by a complex network of signaling molecules such as cytokines and growth factors (Journal of Clinical Investigation, 2014). In pathological conditions like diabetes or peripheral vascular disease, these endogenous pathways are often disrupted, leading to chronic, non-healing wounds (Nature Reviews Disease Primers, 2017). Therapeutic strategies targeting these pathways often involve the application of exogenous growth factors, such as Becaplermin (recombinant human PDGF), to stimulate cellular migration and proliferation (FDA, Regranex Label). Because this term encompasses a broad set of biological cascades rather than a single protein or receptor, it is classified as a physiological process rather than a discrete molecular target.

Other names
Wound healing cascadeTissue repair pathwaysEndogenous regenerative pathwaysPhases of wound healing
02

Mechanism of action

Therapeutic agents modulate these pathways by providing exogenous growth factors to stimulate cell migration and proliferation, or by managing the wound environment to transition from a chronic inflammatory state to a proliferative phase (PubMed, PMC3504384).

03

Biological functions

Cell proliferationImmune responseSignal transductionAngiogenesisTissue remodelingHemostasis
04

Disease associations

Chronic woundsDiabetic foot ulcerVenous leg ulcerBurn injuryPressure ulcer
05

Safety considerations

Risk of malignancy (e.g., boxed warning for Becaplermin)Hypertrophic scarringKeloid formationSystemic absorption of growth factorsInfection risk
06

Interacting drugs

Becaplermin

3 more in the full profile.

07

Biomarkers

Matrix metalloproteinase-9 (MMP-9)Vascular endothelial growth factor (VEGF)Interleukin-1 beta (IL-1β)Tumor necrosis factor-alpha (TNF-α)Tissue inhibitor of metalloproteinases (TIMP)

Beyond the preview

Go deeper on Multiple endogenous wound-healing pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multiple endogenous wound-healing pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call